Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October…
Pharmaceuticals, Biotechnology and Life Sciences
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October…
Innovative solutions for academic, CRO, pharma and biotech customersHOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq:…
• Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in…
NDA for tovorafenib in relapsed or progressive pLGG accepted for FDA priority review PDUFA target action date of April 30,…
PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan…
– Response observed as early as week 1 and durable for up to 16 weeks — Data support important role…
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active…
– Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision,…
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE…
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the…